Clinical safety and Immunogenicity of tumor-targeted, plant-made id-klh conjugate vaccines for follicular lymphoma

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Tusé, Daniel ^a   Ku, Nora ^b   Bendandi, Maurizio ^c   Becerra, Carlos ^d   Collins, Robert ^e   Langford, Nyla ^b   Sancho, Susana Inogés ^f   López Díaz De Cerio, Ascensión ^f   Pastor, Fernando ^g   Kandzia, Romy ^h   Thieme, Frank ^h   Jarczowski, Franziska ^h   Krause, Dieter ^h   Ma, Julian K C ⁱ   Pandya, Shan ⁱ   Klimyuk, Victor ^h   Gleba, Yuri ^h   Butler Ransohoff, John E ^j  

^a DT/Consulting Group   (United States)

^b DAVA Oncology LP Two Lincoln Center   (United States)

^c ROSS UNIVERSITY SCHOOL OF MEDICINE   (Dominica)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g UNIVERSITY OF NAVARRA   (Spain)

^h Icon Genetics GmbH   (Germany)

ⁱ ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^j BAYER PHARMA AG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CANCER VACCINE; IDIOTYPIC ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; PREDNISONE; SARGRAMOSTIM; VINCRISTINE; HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN; POLYSACCHARIDE; VACCINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; FOOT EDEMA; GASTROINTESTINAL TOXICITY; HAND EDEMA; HEAVY CHAIN; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NECK PAIN; NEUROLOGIC DISEASE; NICOTIANA BENTHAMIANA; NONCARDIAC CHEST PAIN; PAIN; PHASE 1 CLINICAL TRIAL; PRURITUS; SALVAGE THERAPY; SKIN REDNESS; WEAKNESS; ADOLESCENT; CELLULAR IMMUNITY; CLINICAL TRIAL; DEMOGRAPHY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATIENT SELECTION; TOBACCO; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DEMOGRAPHY; FEMALE; HEMOCYANIN; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PATIENT SELECTION; POLYSACCHARIDES; TOBACCO; VACCINATION; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84942278930     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/648143     Document Type: Article

References (37)

1. ACS Cancer Facts and Figures 2011, 2011
2. American Cancer Society, ACS Cancer Facts and Figures 2014, American Cancer Society, 2014.
3. T. M. Grogan and M. A. Jaramillo, "Pathology of non-Hodgkins lymphoma, " in Malignant Lymphoma, M. L. Grossbard, Ed. , pp. 1-30, BC Decker, Madrid, Spain, 2002.
4. M. Bendandi, "Aiming at a curative strategy for follicular lymphoma, " CA: A Cancer Journal for Clinicians, vol. 58, no. 5, pp. 305-317, 2008.
5. B. S. Kahl, F. Hong, M. E. Williams et al. , "Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402, " Journal of Clinical Oncology, vol. 32, no. 28, pp. 3096-3102, 2014.
6. L. W. Kwak, M. J. Campbell, D. K. Czerwinski, S. Hart, R. A. Miller, and R. Levy, "Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors, " The New England Journal of Medicine, vol. 327, no. 17, pp. 1209-1215, 1992.
7. M. Bendandi, C. D. Gocke, C. B. Kobrin et al. , "Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma, " Nature Medicine, vol. 5, no. 10, pp. 1171-1177, 1999.
8. S. Inoges, M. Rodriguez-Calvillo, N. Zabalegui et al. , "Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma, " Journal of the National Cancer Institute, vol. 98, no. 18, pp. 1292-1301, 2006.
9. R. Yanez, Y. Barrios, E. Ruiz, R. Cabrera, and F. Diaz-Espada, "Anti-idiotypic immunotherapy in follicular lymphoma patients: results of a long follow-up study, " Journal of Immunotherapy, vol. 31, no. 3, pp. 310-312, 2008.
10. C. H. Redfern, T. H. Guthrie, A. Bessudo et al. , "Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkins lymphoma resulting in durable clinical responses, " Journal of Clinical Oncology, vol. 24, no. 19, pp. 3107-3112, 2006.
11. A. A. Mccormick, M. H. Kumagai, K. Hanley et al. , "Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 2, pp. 703-708, 1999.
12. A. A. McCormick, S. Reddy, S. J. Reinl et al. , "Plant-produced idiotype vaccines for the treatment of non-Hodgkins lymphoma: safety and immunogenicity in a phase I clinical study, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 29, pp. 10131-10136, 2008.
13. M. Bendandi, S. Marillonnet, R. Kandzia et al. , "Rapid, highyield production in plants of individualized idiotype vaccines for non-Hodgkins lymphoma, " Annals of Oncology, vol. 21, no. 12, pp. 2420-2427, 2010.
14. M. Bendandi, "Idiotype vaccines for lymphoma: proof-ofprinciples and clinical trial failures, " Nature Reviews Cancer, vol. 9, no. 9, pp. 675-681, 2009.
15. S. S. Neelapu and L. W. Kwak, "Vaccine therapy for B-cell lymphomas: next-generation strategies, " Hematology/American Society of Hematology. Education Program, pp. 243-249, 2007.
16. D. Tuse, "Safety of plant-made pharmaceuticals: product development and regulatory considerations based on case studies of two autologous human cancer vaccines, " Human Vaccines, vol. 7, no. 3, pp. 322-330, 2011.
17. Y. Y. Gleba, D. Tuse, and A. Giritch, "Plant viral vectors for delivery by Agrobacterium, " Current Topics in Microbiology and Immunology, vol. 375, pp. 155-192, 2014.
18. A. Giritch, S. Marillonnet, C. Engler et al. , "Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 40, pp. 14701-14706, 2006.
19. V. Klimyuk, G. Pogue, S. Herz, J. Butler, and H. Haydon, "Production of recombinant antigens and antibodies in Nicotiana benthamiana using magnifection technology: GMP-compliant facilities for small-and large-scale manufacturing, " Current Topics in Microbiology and Immunology, vol. 375, pp. 127-154, 2014.
20. US Food and Drug Administration, United States Code of Federal Regulations, Title 21 (Food and Drugs), Part 210: Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs, vol. 4, US Food and Drug Administration, 2014.
21. US Food and Drug Administration, United States Code of Federal Regulations, Title 21 (Food and Drugs), Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals, vol. 4, US Food and Drug Administration, 2014.
22. S. Marillonnet, C. Thoeringer, R. Kandzia, V. Klimyuk, and Y. Gleba, "Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants, " Nature Biotechnology, vol. 23, no. 6, pp. 718-723, 2005.
23. CBER, FDA Guidance for Industry, Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, Center for Biologics Evaluation and Research, 2007.
24. ICH, Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance, ICH, 1996.
25. J. W. Friedberg, P. Cohen, L. Chen et al. , "Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkins lymphoma: results from a phase II multicenter, single-agent study, " Journal of Clinical Oncology, vol. 26, no. 2, pp. 204-210, 2008.
26. B. S. Kahl, N. L. Bartlett, J. P. Leonard et al. , "Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study, " Cancer, vol. 116, no. 1, pp. 106-114, 2010.
27. A. Heider and N. Niederle, "Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkins lymphomas, " Anti-Cancer Drugs, vol. 12, no. 9, pp. 725-729, 2001.
28. Leukine, Leukine (sargramostim) monograph, 2013
29. S. Inoges, A. Lopez-Diaz de Cerio, N. Zabalegui et al. , "Prolonged idiotypic vaccination against follicular lymphoma, " Leukemia and Lymphoma, vol. 50, no. 1, pp. 47-53, 2009.
30. H. J. Park and S. S. Neelapu, "Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials, " British Journal of Haematology, vol. 142, no. 2, pp. 179-191, 2008.
31. R. van Ree, M. Cabanes-Macheteau, J. Akkerdaas et al. , " β(1, 2)-xylose and α (1, 3)-fucose residues have a strong contribution in IgE binding to plant glycoallergens, " The Journal of Biological Chemistry, vol. 275, no. 15, pp. 11451-11458, 2000.
32. K. Foetisch, S. Westphal, I. Lauer et al. , "Biological activityof IgE specific for cross-reactive carbohydrate determinants, " Journal of Allergy and Clinical Immunology, vol. 111, no. 4, pp. 889-896, 2003.
33. S. Westphal, D. Kolarich, K. Foetisch et al. , "Molecular characterization and allergenic activity of Lyc e 2 (beta-fructofuranosidase), a glycosylated allergen of tomato, " European Journal of Biochemistry, vol. 270, no. 6, pp. 1327-1337, 2003.
34. A. Koprivova, C. Stemmer, F. Altmann et al. , "Targeted knockouts of Physcomitrella lacking plant-specific immunogenic Nglycans, " Plant Biotechnology Journal, vol. 2, no. 6, pp. 517-523, 2004.
35. M. J. van der Veen, R. van Ree, R. C. Aalberse et al. , "Poor biologic activity of cross-reactive IgE directed to carbohydrate determinants of glycoproteins, " The Journal of Allergy and Clinical Immunology, vol. 100, no. 3, pp. 327-334, 1997.
36. D. Tuse, T. Tu, and K. A. McDonald, "Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes, " BioMed Research International, vol. 2014, Article ID256135, 16 pages, 2014.
37. M. Zamponi, W. Weichel, F. Thieme, and J.-E. Butler-Ransohoff, "Individualized cancer vaccines: an automated systemapproach to sequence identification and vector cloning, " in Proceedings of the 2nd International Conference on High-Throughput Process Development, Avignon, France, 2012.